AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03990584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three irrigation activation methods
Description: passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation
Study NCT03990584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional needle irrigation
Description: conventional needle irrigation
Study NCT02990416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1)
Description: anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
Study NCT02990416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
Study NCT02990416 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ionizing Radiation
Description: Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
Study NCT03296709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPC z
Description: Installation of a preformed pediatric zircona crown
Study NCT03296709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PPC m
Description: Installation of a preformed pediatric metal crown
Study NCT05626764 — intervention group
Intervention type: OTHER
Intervention: QoL & irAEs determinants
Description: Assesment of the QoL \& irAEs determinants in patients diagnosed with solid tumor and treated in France, Netherlands, Portugal, Spain, with immunotherapy by immune checkpoint inhibitors.
Study NCT05626764 — intervention group
Intervention type: OTHER
Intervention: QoL & irAEs determinants
Description: Assesment of the QoL \& irAEs determinants in patients diagnosed with hematologic cancer and treated in France, Netherlands, Portugal, Spain, by CAR-T cells.
Study NCT00553098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given IV
Study NCT00553098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo HCT
Study NCT00553098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT
Study NCT00553098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV
Study NCT00553098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00553098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study
Study NCT00553098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV
Study NCT00553098 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo low dose TBI
Study NCT03484338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy
Description: ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
Study NCT03484338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Resolution Therapy
Description: ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
Study NCT02766179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is used for 6 weeks
Study NCT02766179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnoguard
Description: Somnoguard is used for 6 weeks
Study NCT02281760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
Study NCT02281760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
Study NCT04665622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eye-Tracking / Neuropsychological evaluations
Description: Use of Eye-Tracking / Neuropsychological évaluations in 4 groups
Study NCT02635724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Study NCT00960752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gp100
Description: 1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
Study NCT00960752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R848 gel
Description: Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
Study NCT00960752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGE-3
Description: 1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
Study NCT02111837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula
Study NCT02111837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard infant formula with PL1
Study NCT02111837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard infant formula with PL2
Study NCT01455025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor granulocyte-colony stimulating factor
Description: Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.~Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5
Study NCT01468779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
Study NCT01468779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study NCT03491098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone Furoate spray
Description: Mometasone Furoate spray one puff in each nostril daily for 8 weeks~hypertonic sea water solution spray one puff in each nostril daily for (8) weeks.
Study NCT03491098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisolone sodium phosphate 15mg
Description: three times per day for 1 week then gradual withdrawal over 2 weeks
Study NCT03491098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hypertonic sea water solution spray
Description: one puff in each nostril daily for 8 weeks
Study NCT03748602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic outlet decompression
Description: TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
Study NCT02378532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.
Study NCT02378532 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
Study NCT02378532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
Study NCT01616771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Macintosh laryngoscope
Description: Glottis view assessment by direct visualization using Macintosh laryngoscope
Study NCT01616771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GVL selected by weight
Description: Glottis view assessment by GVL selected by weight which is usually selected first
Study NCT01616771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: smaller sized GVL
Description: Glottis view assessment by GVL which is smaller in one size than GVL selected by age
Study NCT01006317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinical skills training
Description: In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
Study NCT01006317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education
Description: In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
Study NCT01006317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: financial
Description: In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
Study NCT00770432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350
Description: Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
Study NCT00770432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, maltodextrin 500 powder for solution
Description: Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
Study NCT04093921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET-based therapy
Description: see previous
Study NCT04093921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: To include all recommended outpatient treatments
Study NCT04093921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: To include all recommended outpatient treatments
Study NCT03361826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro MST with Cool TwinCoil
Description: MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
Study NCT03361826 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DBT
Description: Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
Study NCT03361826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
Study NCT02875301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 150 Minutes Week
Description: This group will complete aerobic based exercise 150 minutes per week. Participants will obtain minutes through supervised on site exercise and home based exercise. An exercise duration of 30 minutes will be achieved by the forth week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise was been shifted to home based.
Study NCT02875301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 225 Minutes Week
Description: This group will complete aerobic based exercise 225 minutes per week. Participants will obtain minutes through supervised on site exercise and home base exercise. A walking duration of 45 minutes will be achieved by the seventh week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise has been shifted to home based.
Study NCT02875301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretch and Tone
Description: The control condition will focus on improving balance, flexibility, and strength. This group will obtain 150 minutes per week via in person sessions, zoom sessions and home based stretching. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.
Study NCT04154215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT FDG brain scan
Description: Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated.
Study NCT01767935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Description: Undergo cryosurgery
Study NCT01767935 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01767935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02999425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational intervention
Study NCT02861144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ma ka hana ka ̒ike
Description: Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
Study NCT02861144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hanapū Provider Toolbox
Description: Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir-Ritonavir
Description: Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or >44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
Study NCT04381936 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent plasma
Description: Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
Study NCT04381936 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin
Description: Intravenous immunoglobulin (IVIg) for children >44 weeks gestational age and \<18 years with PIMS-TS only (see Protocol for dosage)
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic neutralising antibodies
Description: Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
Study NCT04381936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.